Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CMV Assay Clear all
Terminated No phase listed Observational

Clinical Performance Evaluation of DxN CMV Assay

NCT03127787
View directory record Official record
Conditions
Cytomegalovirus
Interventions
CMV Assay
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 10, 2026, 5:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detection of Cytomegalovirus Virus in Neonates

NCT03251261
View directory record Official record
Conditions
CMV
Interventions
illumigene CMV assay, illumipro-10
Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
Up to 20 Days
Enrollment
1,615 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Birmingham, Alabama • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 13, 2019 · Synced Sep 10, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

NCT04017962
View directory record Official record
Conditions
CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions
Letermovir Pill, blood draw
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 10, 2026, 5:08 AM EDT
Recruiting Phase 2 Interventional

CMV Immunity Monitoring in Lung Transplant Recipients

NCT05708755
View directory record Official record
Conditions
Lung Transplant; Complications
Interventions
Cytomegalovirus T Cell Immunity Panel (CMV-TCIP), Donor-Derived Cell-Free DNA (dd-cfDNA) Assay, Valganciclovir
Device · Diagnostic Test · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 10, 2026, 5:08 AM EDT
Completed Phase 3 Interventional

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

NCT00006145
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 10, 2026, 5:08 AM EDT
Terminated No phase listed Observational

Clinical Evaluation of the QuantiFERON CMV Assay

NCT03502161
View directory record Official record
Conditions
CMV
Interventions
QuantiFERON CMV Assay
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 10, 2026, 5:08 AM EDT
Completed No phase listed Observational

CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

NCT03924219
View directory record Official record
Conditions
Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV
Interventions
CMV T cell Immunity Assay
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
0 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 10, 2026, 5:08 AM EDT
Recruiting Phase 2 Interventional

CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT

NCT06453460
View directory record Official record
Conditions
CMV, Allogeneic Stem Cell Transplantation
Interventions
Letermovir, CMV T Cell Immunity Panel (CMV-TCIP), CMV DNA PCR
Drug · Device · Diagnostic Test
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 10, 2026, 5:08 AM EDT
Completed No phase listed Observational

Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

NCT05238220
View directory record Official record
Conditions
Kidney Transplant; Complications
Interventions
Valganciclovir
Drug
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 10, 2026, 5:08 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant

NCT03570411
View directory record Official record
Conditions
CMV
Interventions
T-SPOT®.CMV Test
Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 10, 2026, 5:08 AM EDT
Completed No phase listed Observational

Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation

NCT02470208
View directory record Official record
Conditions
Infection
Interventions
Not listed
Lead sponsor
Oxford Immunotec
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 10, 2026, 5:08 AM EDT